PLUS THERAPEUTICS, INC. (PSTV): Nasdaq/NYSE listing notice — Plus Therapeutics receives Nasdaq delisting notice for bid price below $1.00

PLUS THERAPEUTICS, INC.

Nasdaq notified Plus Therapeutics on May 16, 2025 of non-compliance with minimum bid price rule (closing bid < $1.00 for 30 consecutive days).
Initial compliance period ends November 12, 2025; must close at $1.00+ for 10 consecutive business days.
If not cured by Nov 12, may be eligible for additional 180-day period if meets other listing standards.
Company will consider options including reverse stock split to regain compliance; no assurance of success.
Potential delisting can be appealed; common stock continues trading on Nasdaq during process.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 16, 2025, Plus Therapeutics, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). Nasdaq’s notice has no immediate effect on the listing or trading of the Company’s common stock. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided an initial compliance period of 180 ca

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-074374

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.